Zymeworks Inc. Common Stock (ZYME) Stock Forecast & Price Target
Zymeworks Inc. Common Stock · NASDAQ
$28.12-1.07 (-3.67%)
15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 10 firms covering Zymeworks Inc. Common Stock, 10 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $32.00 to $58.00, a moderate spread. The average target of $42.70 sits 52% above the current $28.12. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.20 next quarter toward $1.17 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS10 ratings
Strong Buy
Strong Buy00%
Buy10100%
Hold00%
Sell00%
Strong Sell00%
Based on 10 analysts giving stock ratings to Zymeworks Inc. Common Stock.
As of Sep, 10 of 10 firms rate ZYME a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ZYME EPS & revenue forecast
EPS · NEXT QUARTER
$0.20
Range $-0.61 – $3.64 · 6 analysts · -136% YoY
Next period, 6 analysts expect Zymeworks Inc. Common Stock to earn $0.20 a share (range $-0.61 – $3.64), versus $-0.55 a year earlier. Full-year consensus is $1.18, growing to $1.17 the year after.
REVENUE · NEXT QUARTER
$89.8M
Range $9.9M – $314.7M · 6 analysts · +3469% YoY
Revenue is expected to reach $89.8M (range $9.9M – $314.7M), +3469.3% year-over-year. Full-year consensus is $304.0M, rising to $353.4M next year.
Top analysts covering Zymeworks Inc. Common Stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ZYME.
#1
Mayank Mamtani
B. Riley Securities · Rank #41
Buy
$44.00+56.5% to target
Overall win rate
50%
+ Follow
#2
Andrew Berens
Leerink Partners · Rank #121
Buy
$58.00+106.3% to target
Overall win rate
56%
+ Follow
#3
RB
Robert Burns
HC Wainwright & Co. · Rank #199
Buy
$55.00+95.6% to target
Overall win rate
41%
+ Follow
#4
Yigal Nochomovitz
Citigroup · Rank #245
Buy
$38.00+35.1% to target
Overall win rate
41%
+ Follow
#5
SW
Stephen Willey
Stifel · Rank #345
Buy
$46.00+63.6% to target
Overall win rate
31%
+ Follow
ZYME stock forecast FAQ
What is ZYME's average 12-month price target?+
The 10 analysts with a live target average $42.70 for Zymeworks Inc. Common Stock over the next 12 months, ranging from a $58.00 high to a $32.00 low.
Is ZYME stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 10 analyst ratings, 10 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ZYME?+
The Street-high target is $58.00 (Leerink Partners), and the Street-low is $32.00 (Citizens). The average of all 10 active targets is $42.70.
How many Wall Street analysts cover ZYME?+
10 analysts have an active rating on Zymeworks Inc. Common Stock, and 10 firms carry a live 12-month price target.
Who is the most accurate analyst covering ZYME?+
Among analysts who currently cover ZYME, Mayank Mamtani of B. Riley Securities has the strongest overall Quantellect track record (Rank #41). Their current call is Buy with a $44.00 target.
What is Zymeworks Inc. Common Stock's projected EPS for next quarter?+
The consensus estimate is $0.20 per share (range $-0.61 – $3.64) across 6 analysts. Full-year EPS is projected at $1.18, rising to $1.17 the following year.
How much revenue is Zymeworks Inc. Common Stock expected to report next quarter?+
Consensus revenue is $89.8M (range $9.9M – $314.7M). Full-year revenue is projected at $304.0M, growing to $353.4M next year.
Have analysts been upgrading or downgrading ZYME lately?+
As of Sep, 10 of 10 firms rate ZYME a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ZYME calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
